Company profile
EpiMedica
Translational biology platform targeting senescence to treat cancer, aging, and age-driven disease.
- Industry
- Biotechnology Research
- Employees
- 3
- Headquarters
- Laguna Hills, California
- Founded
- 2025
- LinkedIn followers
- 859
- Office locations
- 1
EpiMedica company summary
EpiMedica is a company in the Biotechnology Research industry, headquartered in Laguna Hills, California, founded in 2025. On LinkedIn the company has around 3 employees and 859 followers.
What technology does EpiMedica use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About EpiMedica
EpiMedica is a translational biology platform focused on targeting senescence as a core driver of disease across oncology and aging. Our work is grounded in mechanistic and translational research demonstrating that therapy-induced and age-associated senescent cells are biologically active, measurable, and therapeutically actionable. Rather than focusing exclusively on tumor genetics or downstream disease manifestations, we address an underexplored but critical layer of biology: persistent senescent cells within tumors, tissues, and the microenvironment that drive resistance, recurrence, functional decline, and loss of resilience. In oncology, we are advancing an approach we refer to as oncosenescence followed by oncosenolysis — first inducing senescence in malignant cells, then selectively eliminating those senescent cells using senolytic strategies. This framework is supported by in vitro human data and is now being translated into in vivo validation. In parallel, our longevity program targets conserved aging mechanisms, including cellular stress responses, senescence, tissue dysfunction, and system-level decline, with the goal of generating high-quality in vivo data to support long-term clinical development. EpiMedica operates as a platform-driven, execution-focused organization, working with experienced scientists and clinicians through equity-aligned collaborations. Our emphasis is on translational rigor, real biological signal, and data that meaningfully informs therapeutic development — not isolated academic findings. We actively collaborate with in vivo scientists, clinicians, and strategic partners who share an interest in building durable, biology-first solutions to cancer and age-driven disease.
Where is EpiMedica located?
EpiMedica lists 1 location.
Compare companies similar to EpiMedica
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
EpiMedica epi-medica.com | Biotechnology Research | 3 | 2025 | Laguna Hills, California |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about EpiMedica
What does EpiMedica do?
EpiMedica is a translational biology platform focused on targeting senescence as a core driver of disease across oncology and aging. Our work is grounded in mechanistic and translational research demonstrating that therapy-induced and age-associated senescent cells are biologically active, measurable, and therapeutically actionable. Rather than focusing exclusively on tumor genetics or downstream disease manifestations, we address an underexplored but critical layer of biology: persistent senescent cells within tumors, tissues, and the microenvironment that drive resistance, recurrence, functional decline, and loss of resilience. In oncology, we are advancing an approach we refer to as oncosenescence followed by oncosenolysis — first inducing senescence in malignant cells, then selectively eliminating those senescent cells using senolytic strategies. This framework is supported by in vitro human data and is now being translated into in vivo validation. In parallel, our longevity program targets conserved aging mechanisms, including cellular stress responses, senescence, tissue dysfunction, and system-level decline, with the goal of generating high-quality in vivo data to support long-term clinical development. EpiMedica operates as a platform-driven, execution-focused organization, working with experienced scientists and clinicians through equity-aligned collaborations. Our emphasis is on translational rigor, real biological signal, and data that meaningfully informs therapeutic development — not isolated academic findings. We actively collaborate with in vivo scientists, clinicians, and strategic partners who share an interest in building durable, biology-first solutions to cancer and age-driven disease.
How many employees does EpiMedica have?
EpiMedica has around 3 employees on LinkedIn.
Where is EpiMedica headquartered?
EpiMedica is headquartered in Laguna Hills, California.
When was EpiMedica founded?
EpiMedica was founded in 2025.
Build a lead list from companies like EpiMedica
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.